BriaCell Therapeutics Corp. Warrant (BCTXW)

• Market cap: $280K
• 1 day: -4.62%
• 5 days: 35.71%
• 1 month: -36.62%
• 3 months: -21.10%
• 6 months: -71.64%
• Year to date: -66.89%
• 1 year: -81.00%
• 5 years: -87.33%
• 10 years: -87.33%
• Sector: Healthcare
• Industry: Biotechnology

About: BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Employees: 12

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

75% more funds holding

Funds holding: 4 [Q4 2024] → 7 (+3) [Q1 2025]

3.84% more ownership

Funds ownership: 1.26% [Q4 2024] → 5.11% (+3.84%) [Q1 2025]

88% less capital invested

Capital invested by funds: $129K [Q4 2024] → $15.1K (-$114K) [Q1 2025]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2